POTW 8 [EvolutionBlog]

Sorry, I just realized I never got around to posting the link to the new Problem of the Week. I’ve generally been impressed with the comments that have been left on previous POTWs, so hopefully folks will find this one interesting as well. I think it’s a little bit easier than the last two, but you do have to look at it the right way. Good luck!






from ScienceBlogs http://ift.tt/1EJjQWU

Sorry, I just realized I never got around to posting the link to the new Problem of the Week. I’ve generally been impressed with the comments that have been left on previous POTWs, so hopefully folks will find this one interesting as well. I think it’s a little bit easier than the last two, but you do have to look at it the right way. Good luck!






from ScienceBlogs http://ift.tt/1EJjQWU

Extend Big Dipper’s handle to Spica


Tonight … follow the arc to Arcturus, and drive a spike to Spica. First find the Big Dipper in the northeast in the evening sky, and then follow the curve in the Big Dipper’s handle to the star Arcturus in the constellation Bootes: follow the arc to Arcturus. Now extend the curve in the handle into the southeastern sky: drive a spike to Spica.


By the way, this is the perfect night to identify Spica. The moon will pass quite close to this on April 4, and it’ll be near the star throughout Saturday’s total eclipse of the moon.


Spica in the constellation Virgo looks like one star, but this single point of light is really a multiple star system – with at least two member stars and possibly more – located an estimated distance of 262 light-years away.


Spica’s constellation, Virgo, is so large and rambling and difficult to see that we haven’t marked it.


However, you can look for a little squarish figure even farther to the south than Spica. This square star pattern is the constellation Corvus the Crow (Raven). Check out the star chart below to see where Corvus is in relationship to Spica.


Only two weeks left in our annual fund-raising campaign! Have you donated yet? Help EarthSky keep going.


The little square star pattern near Spica is another constellation, Corvus the Crow.

The little square star pattern near Spica is another constellation, Corvus the Crow.



From the western half of North America, the short-lived total lunar eclipse sits low in the west before sunrise on Saturday, April 4. Be sure to find an unobstructed western horizon. Click for an eclipse calculator.

From the western half of North America, a total eclipse of the moon will sit low in the west before sunrise on Saturday, April 4. Be sure to find an unobstructed western horizon. The bright star near the moon is Spica. Read more about the lunar eclipse.



Bottom line: Use the Big Dipper to arc to the star Arcturus. Then drive a spike to the star Spica on these springtime evenings!


EarthSky astronomy kits are perfect for beginners. Order today from the EarthSky store


Donate: Your support means the world to us






from EarthSky http://ift.tt/1hbweOJ

Tonight … follow the arc to Arcturus, and drive a spike to Spica. First find the Big Dipper in the northeast in the evening sky, and then follow the curve in the Big Dipper’s handle to the star Arcturus in the constellation Bootes: follow the arc to Arcturus. Now extend the curve in the handle into the southeastern sky: drive a spike to Spica.


By the way, this is the perfect night to identify Spica. The moon will pass quite close to this on April 4, and it’ll be near the star throughout Saturday’s total eclipse of the moon.


Spica in the constellation Virgo looks like one star, but this single point of light is really a multiple star system – with at least two member stars and possibly more – located an estimated distance of 262 light-years away.


Spica’s constellation, Virgo, is so large and rambling and difficult to see that we haven’t marked it.


However, you can look for a little squarish figure even farther to the south than Spica. This square star pattern is the constellation Corvus the Crow (Raven). Check out the star chart below to see where Corvus is in relationship to Spica.


Only two weeks left in our annual fund-raising campaign! Have you donated yet? Help EarthSky keep going.


The little square star pattern near Spica is another constellation, Corvus the Crow.

The little square star pattern near Spica is another constellation, Corvus the Crow.



From the western half of North America, the short-lived total lunar eclipse sits low in the west before sunrise on Saturday, April 4. Be sure to find an unobstructed western horizon. Click for an eclipse calculator.

From the western half of North America, a total eclipse of the moon will sit low in the west before sunrise on Saturday, April 4. Be sure to find an unobstructed western horizon. The bright star near the moon is Spica. Read more about the lunar eclipse.



Bottom line: Use the Big Dipper to arc to the star Arcturus. Then drive a spike to the star Spica on these springtime evenings!


EarthSky astronomy kits are perfect for beginners. Order today from the EarthSky store


Donate: Your support means the world to us






from EarthSky http://ift.tt/1hbweOJ

An anonymous Canadian foundation grants $4 million to study naturopathic oncology [Respectful Insolence]

It’s no secret that I don’t have a high opinion of naturopathy. Just enter the word “naturopathy” into the search box of this blog, and you’ll quickly see what I mean. Indeed, when last I mentioned the topic a couple of weeks ago, I was discussing the revelations of Britt Marie Hermes, a former naturopath who realized what a load of pseudoscientific quackery she had bought into, unfortunately, after having finished naturopathy school with a quarter million dollars of debt and having practiced for a while. Her account confirmed my impression of naturopathy as a veritable cornucopia of quackery so massive that it contaminates anything reasonable or science-based within the profession with pure woo. Let’s just put it this way. Homeopathy is an integral part of naturopathic education and practice. That should tell you all you need to know about it. Unfortunately, medical academia appears to have been taken in, as evidenced by recent guidelines in “integrative oncology” authored, in part, by a naturopath, and not just by naturopaths’ claims that naturopaths can be primary care providers and lifestyle counselors.



Last fall, knowing the quackery that naturopathy is, I was disturbed to discover that an unnamed foundation had awarded the Ottawa Integrative Cancer Center (OICC) $4 million to study whether “whether naturopathic therapies such as acupuncture, massage, exercise and nutritional therapies combined with conventional medicine can help prolong or improve the lives of cancer patients.” Specifically, the project is called the Thoracic Peri-Operative Integrative Surgical Care Evaluation (Thoracic POISE) and will study integrative care techniques to use on patients before and after surgery, including a randomized controlled trial to evaluate the techniques and see if they reduce adverse events and improve survival in patients with thoracic malignancies. The trial is being run by Dugald Seely, a naturopath at OICC who has been the topic of discussion here on more than one occasion, most recently for his role in helping to write those misbegotten guidelines by the Society for Integrative Oncology.


Unfortunately, I just found out something that compels me to write again about Dugald Seely and the OICC again, a news report in the Ottawa Citizen entitled Study to assess whether integrative treatment helps cancer patients live longer. When I first saw it, I thought that it was another story on the same study I wrote about last year. I wondered what might have happened to justify a new story. Then I read it:



Can naturopathic therapies help late-stage cancer patients live longer? That question is going to be examined by Canadian and U.S. researchers in the largest study of its kind.


Dugald Seely, executive director of the Ottawa Integrative Cancer Centre and Canadian lead investigator of the Canadian/U.S. Integrative Oncology Study, said 400 people with advanced breast, colorectal, pancreatic and ovarian cancer will be studied at seven clinics across North America over three years. About 100 people from the Ottawa Integrative Cancer Centre are expected to be part of the study.


The observational study should offer “exploratory evidence”, he said, about the effect advanced integrative oncology treatments — naturopathic treatments combined with traditional medical treatment — have on cancer patients. The work, he added, “will provide valuable insight on the role of naturopathic medicine in cancer care and will lead to the conduct of more rigorous randomized controlled trials.”



Now get this. The same unnamed anonymous Canadian foundation that funded the Thoracic POISE study funded this study as well, to the tune of $3 million. Truly, woo has a generous benefactor in this foundation, which is why I’d really, really like to know who’s funding these studies. Since I don’t (and haven’t been able to find out the foundation’s identity), there’s not much I can say there. So instead I looked at the rest of the story. Unfortunately, there wasn’t much detail. What we know is that the study announced this week is going to look at “advanced integrative oncology treatment” (whatever “advanced” means, I have no idea in this context) for patients with late stage cancer. We also know that researchers from the OICC and Bastyr University will jointly conduct the research. Actually, scratch that. I do know what “advanced” integrative treatment means. The news story characterizes it as being aimed at improving survival, enhancing quality of life, reducing side effects from conventional treatment and helping to prevent recurrence. In other words, it’s the “integration” of quackery like intravenous vitamin C and other treatments favored by naturopaths with real, science-based cancer treatment.


I looked for more information, starting with the Thoracic POISE study, which, given that it was nearly six months ago that it was announced, I thought might be underway. Searches of ClinicalTrials.gov were in order. So I first started by searching the database for Dugald Seely’s name. There are currently only two open studies with his name on them, An N-of-1 Study of Homeopathic Treatment of Fatigue in Patients Receiving Chemotherapy and Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality. Yes, Seely is studying homeopathic remedies, or, as I like to call it, doing a clinical trial of magic. At first I thought the melatonin study might be part of the Thoracic POISE study, but I saw rapidly that it had been entered in the database back in 2008, long before the grant received by the OICC. The homeopathy trial doesn’t specify thoracic malignancies and is open to patients with any cancer who are undergoing chemotherapy. So, no, this doesn’t look like it’s part of Thoracic POISE either.


Next, I looked up Health Canada’s Clinical Trials Database, using Seely’s name and various other search terms. I found nothing. Ultimately, I searched for all cancer trials registered in the database. There was nothing that looked like Thoracic POISE there. Why, I can’t help but wonder, is there no registration for this trial in ClinicalTrials.gov or the Health Canada Clinical Trials Database.


So next I looked at this new trial, known as the Canadian/US Integrative Oncology Study (CUSIOS) and involving the OICC, the Canadian College of Naturopathic Medicine (CCNM), and Bastyr University:



The goals of CUSIOS are to observe and measure the overall survival of a cohort of late stage (III and IV) cancer patients who receive AIO treatments and, to describe integrative therapies provided by naturopathic doctors across the cohort. A total of 400 people with advanced breast, colorectal, pancreatic and ovarian cancer will be studied in seven clinics across North America over three years. Each selected site provides comprehensive whole-person care in naturopathic oncology, applying science-based treatment for people with late stage cancer.


Integrative oncology aims to combine the best of conventional and whole-person naturopathic care seamlessly and safely to: improve survival, enhance quality of life, reduce side effects from conventional treatment and help prevent recurrence.


AIO therapies used by naturopathic doctors for late stage cancer are directed at multiple mechanisms to slow tumour progression, prevent metastatic spread and improve survival. The therapies are variable but may include intravenous vitamin C, intravenous artemisinin, intravenous dichloroacetate, mistletoe, hyperthermia, nutritional protocols and the use of immunomodulatory, anti-cancer, and anti-inflammatory natural health products.



In other words, it’s more of the same, “integrating” quackery with real medicine and studying it, except that this time naturopaths will be plying their quackery on patients with advanced-stage cancer who are far more likely to die of their disease. Of course, just to show how much “integrative” oncology has “rebranded” some science-based treatments as somehow being “alternative” or “integrative,” such as nutrition, exercise, and the like. Think of it this way? What is the “natural” about dichloroacetate? What is “integrative” about dichloroacetate? I’ve written about dichloroacetate many times. It’s a targeted chemotherapeutic agent that acts at the level of the Warburg effect, reversing a prominent metabolic derangement present in many cancer cells. It’s been studied in rats and humans and shows mild promise. The only reason it became “alternative” or “integrative” is because in the wake of a promising study in rats of DCA versus brain cancers, because DCA is easily synthesized, opportunists began selling it to desperate cancer patients. They started out selling it as “Pet DCA,” only to be given to pets with cancer. Of course, those selling Pet DCA knew that humans were buying it for themselves and even representing their self-experimentation as legitimate clinical trials. They were not. Ultimately the FDA shut down the people selling DCA, but its reputation had been hopelessly tainted with quackery, which is why, I suspect, it’s now become popular among naturopaths.


And don’t even get me started on high dose intravenous vitamin C. In any case, I searched ClinicalTrials.gov for all of Bastyr’s currently open studies. There is nothing resembling Thoracic POISE or CUSIOS. So what is going on? I don’t know. What I do know is that the OICC has received nearly $7 million to study woo in cancer patients, but I don’t see an open clinical trial yet. I can understand why CUSIOS might not be open yet, but I’m rather shocked that Thoracic POISE shows no signs of being open yet, not showing up in the Health Canada Clinical Trials Database or ClinicalTrials.gov yet, unless I’ve screwed up looking for it, which is always possible. But I doubt it. I searched every variant I could think of. I searched institutions. I searched the American PI of CUSIOS.


Oh, and CUSIOS appears to be a rather pointless study:



“We have chosen to study the outcomes of naturopathic oncology because this area of integrative oncology is currently leading the field in the application of advanced natural medicine therapeutics,” said Leanna Standish, ND, PhD, FABNO, Professor at the Bastyr University Research Institute, and American lead investigator of CUSIOS. “We will collect survival outcomes on late stage cancer patients treated at multiple naturopathic oncology clinics in North America in order to address the fundamentally important question of whether or not AIO has a beneficial impact on survival.”



In other words, they’re spending $3 million to do an observational study with no control. How will they know if naturopathic oncology has anything to do with improved survival if they observe good results? Will they wonder if naturopathic oncology is harmful if they observe worse than expected outcomes? How will they know what to expect anyway? Comparison to historical data is always fraught with difficulty, and only very large differences between what is observed and historical controls are even suggestive of a benefit or detriment.


It’s depressing to think what a waste of money this is, what this money might have done if it had only been directed towards real research in cancer rather than tooth fairy science about naturopathic medicine. $7 million is a lot of money. That’s at least three or four R01-level projects or even around 10-15 R21 preliminary grants. Heck, this much money is on the order of a Stand Up 2 Cancer “Dream Team” grant, or even more.


Of course, the big difference is that the naturopaths benefiting from this largess are anything but a “dream team,” and we don’t even know who’s funding these projects.






from ScienceBlogs http://ift.tt/19JppqB

It’s no secret that I don’t have a high opinion of naturopathy. Just enter the word “naturopathy” into the search box of this blog, and you’ll quickly see what I mean. Indeed, when last I mentioned the topic a couple of weeks ago, I was discussing the revelations of Britt Marie Hermes, a former naturopath who realized what a load of pseudoscientific quackery she had bought into, unfortunately, after having finished naturopathy school with a quarter million dollars of debt and having practiced for a while. Her account confirmed my impression of naturopathy as a veritable cornucopia of quackery so massive that it contaminates anything reasonable or science-based within the profession with pure woo. Let’s just put it this way. Homeopathy is an integral part of naturopathic education and practice. That should tell you all you need to know about it. Unfortunately, medical academia appears to have been taken in, as evidenced by recent guidelines in “integrative oncology” authored, in part, by a naturopath, and not just by naturopaths’ claims that naturopaths can be primary care providers and lifestyle counselors.



Last fall, knowing the quackery that naturopathy is, I was disturbed to discover that an unnamed foundation had awarded the Ottawa Integrative Cancer Center (OICC) $4 million to study whether “whether naturopathic therapies such as acupuncture, massage, exercise and nutritional therapies combined with conventional medicine can help prolong or improve the lives of cancer patients.” Specifically, the project is called the Thoracic Peri-Operative Integrative Surgical Care Evaluation (Thoracic POISE) and will study integrative care techniques to use on patients before and after surgery, including a randomized controlled trial to evaluate the techniques and see if they reduce adverse events and improve survival in patients with thoracic malignancies. The trial is being run by Dugald Seely, a naturopath at OICC who has been the topic of discussion here on more than one occasion, most recently for his role in helping to write those misbegotten guidelines by the Society for Integrative Oncology.


Unfortunately, I just found out something that compels me to write again about Dugald Seely and the OICC again, a news report in the Ottawa Citizen entitled Study to assess whether integrative treatment helps cancer patients live longer. When I first saw it, I thought that it was another story on the same study I wrote about last year. I wondered what might have happened to justify a new story. Then I read it:



Can naturopathic therapies help late-stage cancer patients live longer? That question is going to be examined by Canadian and U.S. researchers in the largest study of its kind.


Dugald Seely, executive director of the Ottawa Integrative Cancer Centre and Canadian lead investigator of the Canadian/U.S. Integrative Oncology Study, said 400 people with advanced breast, colorectal, pancreatic and ovarian cancer will be studied at seven clinics across North America over three years. About 100 people from the Ottawa Integrative Cancer Centre are expected to be part of the study.


The observational study should offer “exploratory evidence”, he said, about the effect advanced integrative oncology treatments — naturopathic treatments combined with traditional medical treatment — have on cancer patients. The work, he added, “will provide valuable insight on the role of naturopathic medicine in cancer care and will lead to the conduct of more rigorous randomized controlled trials.”



Now get this. The same unnamed anonymous Canadian foundation that funded the Thoracic POISE study funded this study as well, to the tune of $3 million. Truly, woo has a generous benefactor in this foundation, which is why I’d really, really like to know who’s funding these studies. Since I don’t (and haven’t been able to find out the foundation’s identity), there’s not much I can say there. So instead I looked at the rest of the story. Unfortunately, there wasn’t much detail. What we know is that the study announced this week is going to look at “advanced integrative oncology treatment” (whatever “advanced” means, I have no idea in this context) for patients with late stage cancer. We also know that researchers from the OICC and Bastyr University will jointly conduct the research. Actually, scratch that. I do know what “advanced” integrative treatment means. The news story characterizes it as being aimed at improving survival, enhancing quality of life, reducing side effects from conventional treatment and helping to prevent recurrence. In other words, it’s the “integration” of quackery like intravenous vitamin C and other treatments favored by naturopaths with real, science-based cancer treatment.


I looked for more information, starting with the Thoracic POISE study, which, given that it was nearly six months ago that it was announced, I thought might be underway. Searches of ClinicalTrials.gov were in order. So I first started by searching the database for Dugald Seely’s name. There are currently only two open studies with his name on them, An N-of-1 Study of Homeopathic Treatment of Fatigue in Patients Receiving Chemotherapy and Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality. Yes, Seely is studying homeopathic remedies, or, as I like to call it, doing a clinical trial of magic. At first I thought the melatonin study might be part of the Thoracic POISE study, but I saw rapidly that it had been entered in the database back in 2008, long before the grant received by the OICC. The homeopathy trial doesn’t specify thoracic malignancies and is open to patients with any cancer who are undergoing chemotherapy. So, no, this doesn’t look like it’s part of Thoracic POISE either.


Next, I looked up Health Canada’s Clinical Trials Database, using Seely’s name and various other search terms. I found nothing. Ultimately, I searched for all cancer trials registered in the database. There was nothing that looked like Thoracic POISE there. Why, I can’t help but wonder, is there no registration for this trial in ClinicalTrials.gov or the Health Canada Clinical Trials Database.


So next I looked at this new trial, known as the Canadian/US Integrative Oncology Study (CUSIOS) and involving the OICC, the Canadian College of Naturopathic Medicine (CCNM), and Bastyr University:



The goals of CUSIOS are to observe and measure the overall survival of a cohort of late stage (III and IV) cancer patients who receive AIO treatments and, to describe integrative therapies provided by naturopathic doctors across the cohort. A total of 400 people with advanced breast, colorectal, pancreatic and ovarian cancer will be studied in seven clinics across North America over three years. Each selected site provides comprehensive whole-person care in naturopathic oncology, applying science-based treatment for people with late stage cancer.


Integrative oncology aims to combine the best of conventional and whole-person naturopathic care seamlessly and safely to: improve survival, enhance quality of life, reduce side effects from conventional treatment and help prevent recurrence.


AIO therapies used by naturopathic doctors for late stage cancer are directed at multiple mechanisms to slow tumour progression, prevent metastatic spread and improve survival. The therapies are variable but may include intravenous vitamin C, intravenous artemisinin, intravenous dichloroacetate, mistletoe, hyperthermia, nutritional protocols and the use of immunomodulatory, anti-cancer, and anti-inflammatory natural health products.



In other words, it’s more of the same, “integrating” quackery with real medicine and studying it, except that this time naturopaths will be plying their quackery on patients with advanced-stage cancer who are far more likely to die of their disease. Of course, just to show how much “integrative” oncology has “rebranded” some science-based treatments as somehow being “alternative” or “integrative,” such as nutrition, exercise, and the like. Think of it this way? What is the “natural” about dichloroacetate? What is “integrative” about dichloroacetate? I’ve written about dichloroacetate many times. It’s a targeted chemotherapeutic agent that acts at the level of the Warburg effect, reversing a prominent metabolic derangement present in many cancer cells. It’s been studied in rats and humans and shows mild promise. The only reason it became “alternative” or “integrative” is because in the wake of a promising study in rats of DCA versus brain cancers, because DCA is easily synthesized, opportunists began selling it to desperate cancer patients. They started out selling it as “Pet DCA,” only to be given to pets with cancer. Of course, those selling Pet DCA knew that humans were buying it for themselves and even representing their self-experimentation as legitimate clinical trials. They were not. Ultimately the FDA shut down the people selling DCA, but its reputation had been hopelessly tainted with quackery, which is why, I suspect, it’s now become popular among naturopaths.


And don’t even get me started on high dose intravenous vitamin C. In any case, I searched ClinicalTrials.gov for all of Bastyr’s currently open studies. There is nothing resembling Thoracic POISE or CUSIOS. So what is going on? I don’t know. What I do know is that the OICC has received nearly $7 million to study woo in cancer patients, but I don’t see an open clinical trial yet. I can understand why CUSIOS might not be open yet, but I’m rather shocked that Thoracic POISE shows no signs of being open yet, not showing up in the Health Canada Clinical Trials Database or ClinicalTrials.gov yet, unless I’ve screwed up looking for it, which is always possible. But I doubt it. I searched every variant I could think of. I searched institutions. I searched the American PI of CUSIOS.


Oh, and CUSIOS appears to be a rather pointless study:



“We have chosen to study the outcomes of naturopathic oncology because this area of integrative oncology is currently leading the field in the application of advanced natural medicine therapeutics,” said Leanna Standish, ND, PhD, FABNO, Professor at the Bastyr University Research Institute, and American lead investigator of CUSIOS. “We will collect survival outcomes on late stage cancer patients treated at multiple naturopathic oncology clinics in North America in order to address the fundamentally important question of whether or not AIO has a beneficial impact on survival.”



In other words, they’re spending $3 million to do an observational study with no control. How will they know if naturopathic oncology has anything to do with improved survival if they observe good results? Will they wonder if naturopathic oncology is harmful if they observe worse than expected outcomes? How will they know what to expect anyway? Comparison to historical data is always fraught with difficulty, and only very large differences between what is observed and historical controls are even suggestive of a benefit or detriment.


It’s depressing to think what a waste of money this is, what this money might have done if it had only been directed towards real research in cancer rather than tooth fairy science about naturopathic medicine. $7 million is a lot of money. That’s at least three or four R01-level projects or even around 10-15 R21 preliminary grants. Heck, this much money is on the order of a Stand Up 2 Cancer “Dream Team” grant, or even more.


Of course, the big difference is that the naturopaths benefiting from this largess are anything but a “dream team,” and we don’t even know who’s funding these projects.






from ScienceBlogs http://ift.tt/19JppqB

Why aren’t there eclipses at every full and new moon?


A lunar eclipse happens when the Earth, sun and moon align in space, with Earth in the middle. At such times, Earth’s shadow falls on the full moon, causing a lunar eclipse.


Shortest total lunar eclipse in the 21st century on April 4, 2015


A solar eclipse happens at the opposite phase of the moon – new moon – when the moon passes between the sun and Earth. Why aren’t there eclipses at every full and new moon?


The moon takes about a month to orbit around the Earth. If the moon orbited in the same plane as the ecliptic – Earth’s orbital plane – we would have two eclipses every month. There’d be an eclipse of the moon at every full moon. And, two weeks later, there’d be an eclipse of the sun at new moon for a total of at least 24 eclipses every year.


But the moon’s orbit is inclined to Earth’s orbit by about 5 degrees. Twice a month the moon intersects the ecliptic – Earth’s orbital plane – at points called nodes. If the moon is going from south to north in its orbit, it’s called an ascending node. If the moon is going form north to south, it’s a descending node. If the full moon or new moon is appreciably close to one of these nodes, then an eclipse is not only possible – but inevitable.


The video below explains an eclipse when the new moon and full moon are aligned with the lunar nodes.



Relative to the moon’s phases, however, the nodes move about 30o westward (clockwise) each month. Hence, the new moon and full moon won’t realign with the nodes again for nearly another six months.


There might be some unfamiliar words in this video, including ecliptic and node. The ecliptic is the plane of Earth’s orbit around the sun. The moon’s orbit is inclined to the plane of the ecliptic. The nodes are the two points every month where the moon’s orbit and the ecliptic intersect.


Even though the moon’s orbit is inclined to that of Earth – and even though there’s not an eclipse with every full and new moon – there are more eclipses than you might think.


There are from four to seven eclipses every year. Some are lunar, some are solar, some are total, and some are partial. All are marvelous to behold – a reminder that we live on a planet – a chance to experience falling in line with great worlds in space!



Photo credit: pizzodisevo







from EarthSky http://ift.tt/1jvbCqP

A lunar eclipse happens when the Earth, sun and moon align in space, with Earth in the middle. At such times, Earth’s shadow falls on the full moon, causing a lunar eclipse.


Shortest total lunar eclipse in the 21st century on April 4, 2015


A solar eclipse happens at the opposite phase of the moon – new moon – when the moon passes between the sun and Earth. Why aren’t there eclipses at every full and new moon?


The moon takes about a month to orbit around the Earth. If the moon orbited in the same plane as the ecliptic – Earth’s orbital plane – we would have two eclipses every month. There’d be an eclipse of the moon at every full moon. And, two weeks later, there’d be an eclipse of the sun at new moon for a total of at least 24 eclipses every year.


But the moon’s orbit is inclined to Earth’s orbit by about 5 degrees. Twice a month the moon intersects the ecliptic – Earth’s orbital plane – at points called nodes. If the moon is going from south to north in its orbit, it’s called an ascending node. If the moon is going form north to south, it’s a descending node. If the full moon or new moon is appreciably close to one of these nodes, then an eclipse is not only possible – but inevitable.


The video below explains an eclipse when the new moon and full moon are aligned with the lunar nodes.



Relative to the moon’s phases, however, the nodes move about 30o westward (clockwise) each month. Hence, the new moon and full moon won’t realign with the nodes again for nearly another six months.


There might be some unfamiliar words in this video, including ecliptic and node. The ecliptic is the plane of Earth’s orbit around the sun. The moon’s orbit is inclined to the plane of the ecliptic. The nodes are the two points every month where the moon’s orbit and the ecliptic intersect.


Even though the moon’s orbit is inclined to that of Earth – and even though there’s not an eclipse with every full and new moon – there are more eclipses than you might think.


There are from four to seven eclipses every year. Some are lunar, some are solar, some are total, and some are partial. All are marvelous to behold – a reminder that we live on a planet – a chance to experience falling in line with great worlds in space!



Photo credit: pizzodisevo







from EarthSky http://ift.tt/1jvbCqP

What a great way to start the day [Life Lines]

I came across this video on YouTube of what must be the most huggable kitty:







from ScienceBlogs http://ift.tt/1F2POZ2

I came across this video on YouTube of what must be the most huggable kitty:







from ScienceBlogs http://ift.tt/1F2POZ2

Star of the week: Mimosa second-brightest in Southern Cross


So far to the south as to be unfamiliar to the ancient Greeks and Romans, this star was not given a name by the classical astronomers, although many today call it Mimosa. The star is formally known as Beta Crucis, the second-brightest star of the Southern Cross. It is sometimes also called “Becrux” by the same naming oddity as with Alpha Crucis (“Acrux”). German astronomer Johann Bayer (1572-1625) is said to have called it Mimosa. Bayer’s reasoning is unclear, but some have suggested that the name might also refer to this star’s blue-white color. Possibly it is reminiscent of the flowers of some members of a large family of tropical trees called mimosa, although most mimosa flowers are purple, red or yellow. Follow the links below to learn about Beta Crucis, aka Becrux or Mimosa, second-brightest star in the Southern Cross.


How to see Beta Crucis


History and mythology of Beta Crucis


Beta Crucis science



Constellation Crux photo by Christopher J Picking in New Zealand. Beta Crucis, or Mimosa, is the second-brightest star in the Cross, on the left in this image. More information about this photo here. Used with permission




How to see Beta Crucis. Blue-white Mimosa (or Beta Crucis, or Becrux) is the 19th brightest star in all the heavens. It is the second-brightest star in the constellation Crux the (Southern) Cross. The Cross is a southern hemisphere constellation, and you will not see Mimosa north of 30 degrees north latitude. That is approximately north of a line that runs from St. Augustine, Florida to New Orleans and Austin. Southern hemisphere observers know and love Mimosa, though, and it is circumpolar for latitudes of about 30 degrees south and higher.


Recommended almanacs can help you find rising and setting time for the Southern Cross star Mimosa into your sky


A midnight culmination occurs when a star is roughly opposite the sun, and ensures that it will be above the horizon a maximum amount of time. This occurs for Mimosa on or about April 2 each year.


The nearer the observer is to the northern observation limit of about 30 degrees, the lower the star will climb into the sky and the shorter the time it will be visible. For example, from Austin, the star barely skirts the horizon for about a half hour at most. Likely it could not be seen at all due to the dimming affects of Earth’s atmosphere. From Miami it rises almost 5 degrees above the horizon and stays up more than 4 hours.


From northern hemisphere locations such as Hawaii, where Mimosa can be seen more easily, it rises in the late evening in late winter, far to the south-southeast and sets in the predawn hours to the south-southwest. By early June it rises before sundown and sets by midnight.



Image Credit: Wikimedia Commons



History and mythology of Beta Crucis. Beta Crucis, or Mimosa, was essentially unknown in classical western mythology, as was the Southern Cross itself. Of course, these stars were well known to the Australian Aboriginal peoples as well as the Islanders of Polynesia and Southern Africa. In Australia, for example, one Aborigine story is that the stars of the Southern Cross are a reminder to the time and place where death first came to mankind. Two of the stars are the glowing eyes of the spirit of death, and the other two are the eyes of the first man to die.


The main stars of Crux including Mimosa, appear on the flags of both Australia and New Zealand, Mimosa appearing as the left side of the cross bar, and Acrux as the bottom of the Cross.



Beta Crucis science. About 353 light-years from Earth, according to data obtained by the Hipparcos mission, Beta Crucis or Mimosa has a visual magnitude or 1.25. It is a giant (or subgiant) blue star, with a spectral classification of B0.5III (B0.5IV), more than 3,000 times brighter than our sun in visible light. However, Mimosa is blue and as such very hot (nearly 28,000 kelvins as estimated by Prof. James Kaler, or about 49,000 degrees F at the surface). Such high temperatures demand that much of the the star’s energy be radiated in ultraviolet and higher frequencies invisible to the human eye. When you take this into account, Mimosa is about 34,000 times more energetic than the sun, according to Kaler.


Mimosa is thought to have a radius about 8 times that of the sun, and a mass 14 times greater. However, these figures are not certain because it is also known that Mimosa has a small stellar companion about which little is known. Since all we can observe is the combined light of both, it is difficult to be precise on all details. The star also is a complex variable with three short periodicities in its light, which varies less than a 20th of a magnitude over several hours. Directly south is the Coal Sack, a distinctive dark nebulosity in the Milky Way, part of Crux.


Position of Mimosa (Beta Crucis) is RA: 12h 47m 44s, dec: -59° 41′ 19″.


Acrux is brightest star in Southern Cross


Southern Cross: Signpost of southern skies






from EarthSky http://ift.tt/1Fzs8Rg

So far to the south as to be unfamiliar to the ancient Greeks and Romans, this star was not given a name by the classical astronomers, although many today call it Mimosa. The star is formally known as Beta Crucis, the second-brightest star of the Southern Cross. It is sometimes also called “Becrux” by the same naming oddity as with Alpha Crucis (“Acrux”). German astronomer Johann Bayer (1572-1625) is said to have called it Mimosa. Bayer’s reasoning is unclear, but some have suggested that the name might also refer to this star’s blue-white color. Possibly it is reminiscent of the flowers of some members of a large family of tropical trees called mimosa, although most mimosa flowers are purple, red or yellow. Follow the links below to learn about Beta Crucis, aka Becrux or Mimosa, second-brightest star in the Southern Cross.


How to see Beta Crucis


History and mythology of Beta Crucis


Beta Crucis science



Constellation Crux photo by Christopher J Picking in New Zealand. Beta Crucis, or Mimosa, is the second-brightest star in the Cross, on the left in this image. More information about this photo here. Used with permission




How to see Beta Crucis. Blue-white Mimosa (or Beta Crucis, or Becrux) is the 19th brightest star in all the heavens. It is the second-brightest star in the constellation Crux the (Southern) Cross. The Cross is a southern hemisphere constellation, and you will not see Mimosa north of 30 degrees north latitude. That is approximately north of a line that runs from St. Augustine, Florida to New Orleans and Austin. Southern hemisphere observers know and love Mimosa, though, and it is circumpolar for latitudes of about 30 degrees south and higher.


Recommended almanacs can help you find rising and setting time for the Southern Cross star Mimosa into your sky


A midnight culmination occurs when a star is roughly opposite the sun, and ensures that it will be above the horizon a maximum amount of time. This occurs for Mimosa on or about April 2 each year.


The nearer the observer is to the northern observation limit of about 30 degrees, the lower the star will climb into the sky and the shorter the time it will be visible. For example, from Austin, the star barely skirts the horizon for about a half hour at most. Likely it could not be seen at all due to the dimming affects of Earth’s atmosphere. From Miami it rises almost 5 degrees above the horizon and stays up more than 4 hours.


From northern hemisphere locations such as Hawaii, where Mimosa can be seen more easily, it rises in the late evening in late winter, far to the south-southeast and sets in the predawn hours to the south-southwest. By early June it rises before sundown and sets by midnight.



Image Credit: Wikimedia Commons



History and mythology of Beta Crucis. Beta Crucis, or Mimosa, was essentially unknown in classical western mythology, as was the Southern Cross itself. Of course, these stars were well known to the Australian Aboriginal peoples as well as the Islanders of Polynesia and Southern Africa. In Australia, for example, one Aborigine story is that the stars of the Southern Cross are a reminder to the time and place where death first came to mankind. Two of the stars are the glowing eyes of the spirit of death, and the other two are the eyes of the first man to die.


The main stars of Crux including Mimosa, appear on the flags of both Australia and New Zealand, Mimosa appearing as the left side of the cross bar, and Acrux as the bottom of the Cross.



Beta Crucis science. About 353 light-years from Earth, according to data obtained by the Hipparcos mission, Beta Crucis or Mimosa has a visual magnitude or 1.25. It is a giant (or subgiant) blue star, with a spectral classification of B0.5III (B0.5IV), more than 3,000 times brighter than our sun in visible light. However, Mimosa is blue and as such very hot (nearly 28,000 kelvins as estimated by Prof. James Kaler, or about 49,000 degrees F at the surface). Such high temperatures demand that much of the the star’s energy be radiated in ultraviolet and higher frequencies invisible to the human eye. When you take this into account, Mimosa is about 34,000 times more energetic than the sun, according to Kaler.


Mimosa is thought to have a radius about 8 times that of the sun, and a mass 14 times greater. However, these figures are not certain because it is also known that Mimosa has a small stellar companion about which little is known. Since all we can observe is the combined light of both, it is difficult to be precise on all details. The star also is a complex variable with three short periodicities in its light, which varies less than a 20th of a magnitude over several hours. Directly south is the Coal Sack, a distinctive dark nebulosity in the Milky Way, part of Crux.


Position of Mimosa (Beta Crucis) is RA: 12h 47m 44s, dec: -59° 41′ 19″.


Acrux is brightest star in Southern Cross


Southern Cross: Signpost of southern skies






from EarthSky http://ift.tt/1Fzs8Rg

Thirty Years of Undergraduate Support through the Greater Research Opportunities Fellowship Program

By Georgette Boddie


Photograph of GRO Alumni Gregory Crawford

GRO Alumni Gregory Crawford



When I came to the Environmental Protection Agency some thirty five years ago, I did not know it would include the wonderful opportunity to impact the lives of so many students. As Program Manager for the Greater Research Opportunities (GRO) Fellowship Program, I have worked with hundreds of Fellows to ensure that they have the support they need while in the program. I began in 1997 when it was called the Minority Academic Institutions Undergraduate Student Fellowships, which targeted underrepresented undergraduate students interested in the environmental sciences. We offered an opportunity for promising undergraduates to pursue these related disciplines as undergraduates with less of a financial burden. Fellows could also participate in a 12-week summer internship at an EPA facility, doing real-world science and engineering.


When I think back to my first group of Fellows (11 students), it is amazing to see that the program has grown to fund up to 40 students per year. And it’s even harder to believe that more than 400 students have been supported through the program.


The most rewarding part is knowing that because of GRO, Fellows were able to gain invaluable experience and find their true calling in the environmental field. Many now work in academia, the federal government, the private sector, non-government organizations and state agencies.


Our GRO Forum shares the stories of our alumni as they continue to protect human health and the environment. There are many that stand out in my mind and a few that have kept in touch with me over the years, keeping me posted about their career journey. Here are just a couple:



  • 1995 Fellow Gregory Crawford is easy to remember because he started before I was managing the program. I first reached out to him requesting information to include in the GRO Forum. He responded almost immediately and we have been in contact ever since!

  • Another that comes to mind is Cynthia Williams, a 2007 Fellow. She has been working toward her doctoral degree in chemistry at the University of California-Davis, with hopes of one day working for EPA. She has also given back to the program on numerous occasions, serving as a peer reviewer evaluating program applicants.


Those are just two examples of many memorable students I’ve been fortunate to get to know, but they all have had impacts on the program.


This year marks more than 30 years that EPA has provided support to undergraduate students through GRO. And with the recent announcement of our 2014 cohort of GRO Fellows, 34 more now have the opportunity to focus on their studies in environmental-related disciplines.


When the time comes for me to retire, I know I’ll be pleased to know that I have made a positive difference in the lives of so many students, and have helped to set their path as future environmental pioneers.


About the Author : Georgette Boddie has worked at EPA for 34 years. During that time she has served in numerous capacities, and in more recent years, as program manager for the GRO Undergraduate Fellowships program. Ms. Boddie has managed hundreds of student fellows throughout her professional career. However she has no doubt touched the lives of thousands.






from Science http://ift.tt/1EDCteG

By Georgette Boddie


Photograph of GRO Alumni Gregory Crawford

GRO Alumni Gregory Crawford



When I came to the Environmental Protection Agency some thirty five years ago, I did not know it would include the wonderful opportunity to impact the lives of so many students. As Program Manager for the Greater Research Opportunities (GRO) Fellowship Program, I have worked with hundreds of Fellows to ensure that they have the support they need while in the program. I began in 1997 when it was called the Minority Academic Institutions Undergraduate Student Fellowships, which targeted underrepresented undergraduate students interested in the environmental sciences. We offered an opportunity for promising undergraduates to pursue these related disciplines as undergraduates with less of a financial burden. Fellows could also participate in a 12-week summer internship at an EPA facility, doing real-world science and engineering.


When I think back to my first group of Fellows (11 students), it is amazing to see that the program has grown to fund up to 40 students per year. And it’s even harder to believe that more than 400 students have been supported through the program.


The most rewarding part is knowing that because of GRO, Fellows were able to gain invaluable experience and find their true calling in the environmental field. Many now work in academia, the federal government, the private sector, non-government organizations and state agencies.


Our GRO Forum shares the stories of our alumni as they continue to protect human health and the environment. There are many that stand out in my mind and a few that have kept in touch with me over the years, keeping me posted about their career journey. Here are just a couple:



  • 1995 Fellow Gregory Crawford is easy to remember because he started before I was managing the program. I first reached out to him requesting information to include in the GRO Forum. He responded almost immediately and we have been in contact ever since!

  • Another that comes to mind is Cynthia Williams, a 2007 Fellow. She has been working toward her doctoral degree in chemistry at the University of California-Davis, with hopes of one day working for EPA. She has also given back to the program on numerous occasions, serving as a peer reviewer evaluating program applicants.


Those are just two examples of many memorable students I’ve been fortunate to get to know, but they all have had impacts on the program.


This year marks more than 30 years that EPA has provided support to undergraduate students through GRO. And with the recent announcement of our 2014 cohort of GRO Fellows, 34 more now have the opportunity to focus on their studies in environmental-related disciplines.


When the time comes for me to retire, I know I’ll be pleased to know that I have made a positive difference in the lives of so many students, and have helped to set their path as future environmental pioneers.


About the Author : Georgette Boddie has worked at EPA for 34 years. During that time she has served in numerous capacities, and in more recent years, as program manager for the GRO Undergraduate Fellowships program. Ms. Boddie has managed hundreds of student fellows throughout her professional career. However she has no doubt touched the lives of thousands.






from Science http://ift.tt/1EDCteG